Advances in COVID-19 Treatment Research Phase 4

Time :


The latest progress in clinical research on Professor Jiang Shanping's fight against COVID-19 epidemic in Sun Yat-sen Hospital of Sun Yat-sen University

The latest progress in clinical research on Professor Jiang Shanping's fight against COVID-19 epidemic in Sun Yat-sen Hospital of Sun Yat-sen University
Since the outbreak of the epidemic, as a veteran in the fight against "SARS", Professor Jiang Shanping, director of the Department of Respiratory Medicine at Sun Yat-sen Memorial Hospital of Sun Yat-sen University, has been paying close attention to the development of the epidemic. He first proposed the treatment plan of "chloroquine phosphate for the treatment of novel coronavirus pneumonia" and participated in the promotion
Related scientific research and clinical research, the program has now been listed as one of the four options for COVID-19 by VWH0 -. Contributed the wisdom and strength of experts from Sun Yat-sen University to the global fight against the epidemic.
As early as January 19 this year, Professor Jiang Shanping also took the lead in undertaking a special project in Guangdong Province to prevent and control novel coronavirus science and technology
Low molecular weight heparin to protect vascular endothelial cells, prevention of pulmonary microvascular embolism in the improvement of severe novel coronavirus
The role of pneumonia in prognosis.
At present, there is no specific drug for COVID-19 in clinical practice. For severe and severe cases, it can improve the success rate of treatment and reduce the mortality rate.
Is the primary target. From the autopsy reports of deceased SARS patients, it was found that pulmonary vascular microthromboembolism was very common, and vascular endothelial cell damage occurred in small and medium-sized pulmonary vessels. Based on this, it is speculated that pulmonary vascular endothelial cell damage and pulmonary vascular microthromboembolism may exist in critical COVID-19 cases. Low-molecular weight heparin is a commonly used anticoagulant drug in clinical practice. At the same time, low-molecular weight heparin has multiple pharmacological effects such as reducing the generation of oxygen free radicals, inhibiting the release of inflammatory mediators, reducing the recruitment of inflammatory cells, and antithrombotic and anticoagulant. Professor Jiang's study was designed as a multicenter, prospective, interventional clinical study. The experimental subjects were severe and critically ill cases of COVID-19, and the subjects were randomly assigned to two groups: the conventional treatment group, which was treated with a conventional regimen according to the consultation opinions of the expert group; the intervention treatment group, based on the consultation opinions of the expert group, combined with low molecular weight heparin. Adjuvant treatment, the program is: 100 IU/kg/time of enoxaparin sodium, subcutaneous injection, once every 12 hours for 7 days; or 0.1mI/10kg/time of nadrocalcin. Subcutaneous injection, once every 12 hours for 7 days (or other varieties of low molecular weight heparin, selected according to the central situation). Primary endpoint: 28-day etiological mortality; secondary clinical endpoint: ① 28-day all-cause mortality, ② SOFA score during treatment ③ organ support intensity, ④ overall hospital stay, ICU stay.
At present, the research protocol has been applied to the treatment protocol of critically ill patients with COVID-19. It can be seen that low molecular weight heparin is the treatment of COVID-19 
One of the important means of critically ill cases is indispensable.